These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

211 related items for PubMed ID: 16932066

  • 21. HER-2 gene amplification in Paget disease of the nipple and extramammary site: a chromogenic in situ hybridization study.
    Bianco MK, Vasef MA.
    Diagn Mol Pathol; 2006 Sep; 15(3):131-5. PubMed ID: 16932067
    [Abstract] [Full Text] [Related]

  • 22. Determination of HER2/neu status in uterine serous papillary carcinoma: Comparative analysis of immunohistochemistry and fluorescence in situ hybridization.
    Santin AD, Bellone S, Van Stedum S, Bushen W, De Las Casas LE, Korourian S, Tian E, Roman JJ, Burnett A, Pecorelli S.
    Gynecol Oncol; 2005 Jul; 98(1):24-30. PubMed ID: 15894362
    [Abstract] [Full Text] [Related]

  • 23. Amplification of c-erbB2 oncogene: a major prognostic indicator in uterine serous papillary carcinoma.
    Santin AD, Bellone S, Van Stedum S, Bushen W, Palmieri M, Siegel ER, De Las Casas LE, Roman JJ, Burnett A, Pecorelli S.
    Cancer; 2005 Oct 01; 104(7):1391-7. PubMed ID: 16116605
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. HER-2/neu and topoisomerase IIa gene amplification and protein expression in invasive breast carcinomas: chromogenic in situ hybridization and immunohistochemical analyses.
    Bhargava R, Lal P, Chen B.
    Am J Clin Pathol; 2005 Jun 01; 123(6):889-95. PubMed ID: 15899781
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. HER2/neu expression and gene alterations in pancreatic ductal adenocarcinoma: a comparative immunohistochemistry and chromogenic in situ hybridization study based on tissue microarrays and computerized image analysis.
    Tsiambas E, Karameris A, Dervenis C, Lazaris AC, Giannakou N, Gerontopoulos K, Patsouris E.
    JOP; 2006 May 09; 7(3):283-94. PubMed ID: 16685109
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. Epidermal growth factor receptor and HER-2/neu status by immunohistochemistry and fluorescence in situ hybridization in adenocarcinomas of the biliary tree and gallbladder.
    Shafizadeh N, Grenert JP, Sahai V, Kakar S.
    Hum Pathol; 2010 Apr 09; 41(4):485-92. PubMed ID: 20040392
    [Abstract] [Full Text] [Related]

  • 30. HER-2/neu analysis in breast cancer bone metastases.
    Zustin J, Boddin K, Tsourlakis MC, Burandt E, Mirlacher M, Jaenicke F, Izbicki J, Ruether W, Rueger JM, Bokemeyer C, Simon R, Sauter G.
    J Clin Pathol; 2009 Jun 09; 62(6):542-6. PubMed ID: 19474354
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. Overexpression/amplification of HER-2/neu is uncommon in invasive carcinoma of the uterine cervix.
    Rosty C, Couturier J, Vincent-Salomon A, Genin P, Fréneaux P, Sigal-Zafrani B, Sastre-Garau X.
    Int J Gynecol Pathol; 2004 Jan 09; 23(1):13-7. PubMed ID: 14668544
    [Abstract] [Full Text] [Related]

  • 33. Potential for molecular targeted therapy of HER-2/neu for invasive bladder cancer: examination of gene amplification by fluorescence in situ hybridization.
    Yamada Y, Naruse K, Nakamura K, Aoki S, Taki T, Tobiume M, Zennami K, Katsuda R, Hirano M, Hayashida K, Mizumukai E, Nanaura H, Honda N.
    Oncol Rep; 2007 Nov 09; 18(5):1183-7. PubMed ID: 17914570
    [Abstract] [Full Text] [Related]

  • 34. HER-2/neu evaluation by immunohistochemistry and fluorescence in situ hybridization in breast cancer: implications for daily laboratory practice.
    Larsimont D, Di Leo A, Rouas G, Paesmans M, Ferreira-Filho F, Bernard C, Cardoso F, Verhest A, Piccart MJ, Gancberg D.
    Anticancer Res; 2002 Nov 09; 22(4):2485-90. PubMed ID: 12174949
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. Detection of Her-2/neu oncogene in breast carcinoma by chromogenic in situ hybridization in cytologic specimens.
    Lin F, Shen T, Prichard JW.
    Diagn Cytopathol; 2005 Dec 09; 33(6):376-80. PubMed ID: 16299744
    [Abstract] [Full Text] [Related]

  • 37. Non-invasive (intracapsular) carcinoma ex pleomorphic adenoma: recognition of focal carcinoma by HER-2/neu and MIB1 immunohistochemistry.
    Di Palma S, Skálová A, Vanìèek T, Simpson RH, Stárek I, Leivo I.
    Histopathology; 2005 Feb 09; 46(2):144-52. PubMed ID: 15693886
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. Immunohistochemical determination of HER-2/neu expression in invasive breast carcinoma.
    Vang R, Cooley LD, Harrison WR, Reese T, Abrams J.
    Am J Clin Pathol; 2000 May 09; 113(5):669-74. PubMed ID: 10800399
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 11.